Comparing chemo combinations before surgery or watch-and-wait for high-risk rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a stronger chemo combination (FOLFOXIRI) versus the standard ones (CAPOX or FOLFOX), both followed by chemoradiation, then surgery or a watch-and-wait approach for people with high-risk locally advanced rectal cancer. The goal is to see which approach works better at preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of rectal cancer that is locally advanced and considered high risk (your doctor will confirm this with MRI scans).
- You are well enough to have a daily life with only minor limitations (WHO performance score 0 or 1).
- Your doctor believes you can handle the strong chemo combination (FOLFOXIRI) safely.
- The cancer is not spread to other parts of the body (no metastasis).
- You have not had chemotherapy in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two chemotherapy combinations given with surgery for locally advanced rectal cancer. It aims to find out which approach works better and is safer for shrinking and controlling the cancer before or around the time of treatment.
This trial tests giving a strong chemotherapy combination (FOLFIRINOX) followed by radiation before surgery for locally advanced rectal cancer. If you have stage 3 or high-risk stage 2 rectal cancer that has not spread, this approach may shrink the tumor and improve outcomes.
This Phase 3 trial compares different chemotherapy and radiation combinations given before surgery for locally advanced rectal cancer, to see which one works better. It may help people get a tumor removed completely (R0 resection) and improve outcomes while comparing treatment safety and effectiveness.
This Phase 3 study compares giving chemotherapy before rectal surgery versus giving it after surgery, using a tailored plan based on your risk. The goal is to see which timing helps more people with locally advanced rectal cancer stay cancer-free and live longer.
This trial tests whether combining an immunotherapy drug (PD-1 inhibitor) with intense chemotherapy before surgery works better than standard chemotherapy alone for a certain type of locally advanced rectal cancer. It is for people whose tumors have normal DNA repair (pMMR) and are very low in the rectum.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.